Instil Bio, Inc. (TIL): Price and Financial Metrics

Instil Bio, Inc. (TIL): $12.05

0.30 (+2.55%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add TIL to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#205 of 358

in industry

TIL Price/Volume Stats

Current price $12.05 52-week high $16.19
Prev. close $11.75 52-week low $6.07
Day low $11.68 Volume 8,271
Day high $12.11 Avg. volume 42,384
50-day MA $9.40 Dividend yield N/A
200-day MA $9.55 Market Cap 78.37M

TIL Stock Price Chart Interactive Chart >


Instil Bio, Inc. (TIL) Company Bio


Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.


TIL Latest News Stream


Event/Time News Detail
Loading, please wait...

TIL Latest Social Stream


Loading social stream, please wait...

View Full TIL Social Stream

Latest TIL News From Around the Web

Below are the latest news stories about INSTIL BIO INC that investors may wish to consider to help them evaluate TIL as an investment opportunity.

Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split

DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that a 1-for-20 reverse stock split of its outstanding shares of common stock will be effective as of 5:00 p.m. Eastern Time on Thursday, December 7, 2023. The Company’s common stock will begin trading on a reverse stock spli

Yahoo | December 5, 2023

Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported its third quarter 2023 financial results and provided a corporate update. Recent Highlights and Anticipated Milestones: Presented novel preclinical data at SITC 2023 Annual Meeting demonstrating that its CoStimulatory Antigen Receptor (CoStAR)

Yahoo | November 13, 2023

Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting

Presented novel preclinical data showing that CoStAR enhances activity of CD4+ T cells in multiple ways to broaden anti-tumor response and support CD8+ T cellsDALLAS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported two poster presentations at the SITC 2023 Annual Meeting demonstrating that its prop

Yahoo | November 6, 2023

After Plunging -18.52% in 4 Weeks, Here's Why the Trend Might Reverse for Instil Bio, Inc. (TIL)

The heavy selling pressure might have exhausted for Instil Bio, Inc. (TIL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Yahoo | August 31, 2023

Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational in Manchester, UK manufacturing facility with additional process improvements DALLAS, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of pat

Yahoo | August 14, 2023

Read More 'TIL' Stories Here

TIL Price Returns

1-mo 12.83%
3-mo 62.84%
6-mo 32.94%
1-year -23.70%
3-year N/A
5-year N/A
YTD 58.14%
2023 -39.52%
2022 -96.32%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!